Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001364173 | SCV001560308 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2022-10-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002395817 | SCV002701097 | uncertain significance | Cardiovascular phenotype | 2024-04-28 | criteria provided, single submitter | clinical testing | The p.A492V variant (also known as c.1475C>T), located in coding exon 12 of the JAG1 gene, results from a C to T substitution at nucleotide position 1475. The alanine at codon 492 is replaced by valine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004550087 | SCV004756166 | uncertain significance | JAG1-related disorder | 2024-01-11 | no assertion criteria provided | clinical testing | The JAG1 c.1475C>T variant is predicted to result in the amino acid substitution p.Ala492Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.017% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/20-10629291-G-A). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |